FOXO Technologies™ Announces Resignation of Taylor Fay, Chief Operating Officer
April 18 2023 - 7:00AM
Business Wire
FOXO Technologies Inc. (NYSEAM: FOXO), a leader in
commercializing epigenetic biomarkers of health and aging, today
announced the resignation of Taylor Fay as Chief Operating Officer
of the Company, effective April 28, 2023.
“I am extremely proud of our achievements throughout Taylor’s
tenure at FOXO,” said Tyler Danielson, interim CEO, and Chief
Technology Officer at FOXO. “His leadership and work ethic inspired
those around him, and we are a more talented and dedicated team
because of his contributions. The Board and executive leadership
thank Taylor for his leadership and wish him well in his future
endeavors.”
“Throughout my tenure at FOXO, I have worked alongside an
exceptional team dedicated to driving our organization's success,”
said Mr. Fay. “It has been a sincere honor to serve as COO and I am
excited for FOXO’s future. I look forward to continuing to support
the company’s leadership any way I can.”
About FOXO Technologies Inc. (“FOXO”)
FOXO is a biotechnology company dedicated to improving human
health and longevity through the development of cutting-edge
technology and product solutions for various industries, including
life insurance. FOXO's epigenetic technology applies AI to DNA
methylation to identify molecular biomarkers of human health and
aging. FOXO is committed to leveraging the latest advancements in
science and technology to help people live better, longer lives.
For more information about FOXO, visit
www.foxotechnologies.com.
Forward-Looking Statements
This press release contains certain forward-looking statements
for purposes of the “safe harbor” provisions under the United
States Private Securities Litigation Reform Act of 1995. Any
statements other than statements of historical fact contained
herein, including statements as to future results of operations and
financial position, planned products and services, business
strategy and plans, objectives of management for future operations
of FOXO, market size and growth opportunities, competitive position
and technological and market trends, are forward-looking
statements. Such forward-looking statements include, but not
limited to, expectations, hopes, beliefs, intentions, plans,
prospects, financial results or strategies regarding FOXO and the
future held by the management team of FOXO, the future financial
condition and performance of FOXO and the products and markets and
expected future performance and market opportunities of FOXO. These
forward-looking statements generally are identified by the words
“anticipate,” “believe,” “could,” “expect,” “estimate,” “future,”
“intend,” “strategy,” “may,” “might,” “strategy,” “opportunity,”
“plan,” project,” “possible,” “potential,” “project,” “predict,”
“scales,” “representative of,” “valuation,” “should,” “will,”
“would,” “will be,” “will continue,” “will likely result,” and
similar expressions, but the absence of these words does not mean
that a statement is not forward-looking. Forward-looking statements
are predictions, projections and other statements about future
events that are based on current expectations and assumptions and,
as a result, are subject to risks and uncertainties. Many factors
could cause actual future events to differ materially from the
forward-looking statements in this press release, including but not
limited to: (i) the risk of changes in the competitive and highly
regulated industries in which FOXO operates, variations in
operating performance across competitors or changes in laws and
regulations affecting FOXO’s business; (ii) the ability to
implement FOXO’s business plans, forecasts, and other expectations;
(iii) the ability to obtain financing if needed; (iv) the ability
to maintain its NYSE American listing; (v) the risk that FOXO has a
history of losses and may not achieve or maintain profitability in
the future; (vi) potential inability of FOXO to establish or
maintain relationships required to advance its goals or to achieve
its commercialization and development plans; (vii) the
enforceability of FOXO’s intellectual property, including its
patents and the potential infringement on the intellectual property
rights of others; and (viii) the risk of downturns and a changing
regulatory landscape in the highly competitive biotechnology
industry or in the markets or industries in which FOXO’s
prospective customers operate, including the highly regulated
insurance industry. The foregoing list of factors is not
exhaustive. Readers should carefully consider the foregoing factors
and the other risks and uncertainties discussed in FOXO’s most
recent reports on Forms 10-K and 10-Q, particularly the “Risk
Factors” sections of those reports, and in other documents FOXO has
filed, or will file, with the SEC. These filings identify and
address other important risks and uncertainties that could cause
actual events and results to differ materially from those contained
in the forward-looking statements. Forward-looking statements speak
only as of the date they are made. Readers are cautioned not to put
undue reliance on forward-looking statements, and FOXO assumes no
obligation and do not intend to update or revise these
forward-looking statements, whether as a result of new information,
future events, or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230418005576/en/
Contacts / Investor Relations Matthew Hausch, Cody Slach
Gateway Investor Relations (949) 574-3860 FOXO@gatewayir.com
FOXO Technologies (AMEX:FOXO)
Historical Stock Chart
From Jun 2024 to Jul 2024
FOXO Technologies (AMEX:FOXO)
Historical Stock Chart
From Jul 2023 to Jul 2024